Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel in connection with the combination of itm8 and its current portfolio company AddPro
Mandate

Vinge advises Axcel in connection with the combination of itm8 and its current portfolio company AddPro

May 30, 2022 M&A

Axcel, in partnership with Chr. Augustinus Fabrikker, has agreed to acquire the Danish digital transformation partner, itm8, to create a northern European group within end-to-end IT services through a combination with Axcel-owned AddPro.

Over the years, itm8 and AddPro have individually built strong brands and the aim is to jointly expand the offering of IT-services in the northern European area. Vinge assisted Axcel as lead legal advisor in regard to the divestment of AddPro and Swedish law aspects of the combination with itm8.

The transaction is subject to customary regulatory approvals and is expected to close in Q3 2022.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson and Nina Fathjalali (M&A), and Viktoria Owetz Leyva, Sara Dahlros Sköld, Christoffer Widström, Julia Hagelberg and Klara Lundquist (VDR).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026